Literature DB >> 25905934

Percutaneous ablation therapy of hepatocellular carcinoma with irreversible electroporation: MRI findings.

Vincenza Granata1, Roberta Fusco, Orlando Catalano, Mauro Piccirillo, Mario De Bellis, Francesco Izzo, Antonella Petrillo.   

Abstract

OBJECTIVE: Irreversible electroporation is a new ablation modality. Our purpose was to describe the MRI findings after irreversible electroporation treatment of hepatocellular carcinoma (HCC). SUBJECTS AND METHODS: In an 18-month period, we treated 24 HCC lesions in 20 patients who were not candidates for surgery. MRI was performed before and 1 month after irreversible electroporation. We used the liver-specific contrast medium gadoxetic acid. We evaluated the size, shape, signal intensity (T1-weighted, T2-weighted, and diffusion-weighted imaging), dynamic contrast enhancement pattern, and signal behavior during the liver-specific phase. Changes in the perilesional parenchyma, perfusion abnormalities, and complications were also recorded.
RESULTS: According to the modified Response Evaluation Criteria in Solid Tumors system, 22 of 24 lesions had a complete response, and two lesions showed a partial response and were retreated. The lesions showed a mean size increase of 10%, with a round or oval shape. On the T1-weighted images, we observed a hyperintense core and a hypointense rim. On the T2-weighted sequences, the signal was heterogeneously hypointense. On diffusion-weighted images, 83% of lesions showed restricted diffusion, with b values of 0-800 s/mm(2), whereas in 17% of the lesions, the signal was not clearly discernible for different b values. The apparent diffusion coefficient values did not show statistically significant differences between the baseline (800-1020 × 10(-3) mm(2)/s) and the reassessment after 1 month (900-1100 × 10(-3) mm(2)/s). The necrotic area did not show a signal increase after contrast material injection. Perfusion abnormalities, such as areas of transient hepatic intensity difference, were present in the tissue adjacent to six treated lesions. In two patients, a reduced or absent concentration of the contrast medium was observed during the liver-specific phase around the ablation zone. One patient had an arteriovenous shunt and another had biliary duct dilatation.
CONCLUSION: MRI detects characteristic morphologic and functional changes after irreversible electroporation treatment.

Entities:  

Keywords:  MRI; ablation; hepatocellular carcinoma; irreversible electroporation; liver; posttreatment assessment

Mesh:

Substances:

Year:  2015        PMID: 25905934     DOI: 10.2214/AJR.14.12509

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  28 in total

1.  Preclinical and clinical evaluation of the liver tumor irreversible electroporation by magnetic resonance imaging.

Authors:  Matteo Figini; Xifu Wang; Tianchu Lyu; Zhanliang Su; Daniele Procissi; Vahid Yaghmai; Andrew C Larson; Zhuoli Zhang
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

2.  Transcatheter intra-arterial perfusion (TRIP)-MRI biomarkers help detect immediate response to irreversible electroporation of rabbit VX2 liver tumor.

Authors:  Matteo Figini; Kang Zhou; Liang Pan; Chong Sun; Bin Wang; Su Hu; Jia Yang; Junjie Shangguan; Aydin Eresen; Yury Velichko; Vahid Yaghmai; Zhuoli Zhang
Journal:  Magn Reson Med       Date:  2019-12-18       Impact factor: 4.668

3.  Multimodality imaging to assess immediate response following irreversible electroporation in patients with malignant hepatic tumors.

Authors:  Katsutoshi Sugimoto; Fuminori Moriyasu; Kazuhiro Saito; Yoshiyuki Kobayashi; Takao Itoi
Journal:  J Med Ultrason (2001)       Date:  2016-12-08       Impact factor: 1.314

4.  Peribiliary liver metastases MR findings.

Authors:  Vincenza Granata; Roberta Fusco; Orlando Catalano; Antonio Avallone; Maddalena Leongito; Francesco Izzo; Antonella Petrillo
Journal:  Med Oncol       Date:  2017-06-01       Impact factor: 3.064

Review 5.  Management of cutaneous melanoma: radiologists challenging and risk assessment.

Authors:  Vincenza Granata; Igino Simonetti; Roberta Fusco; Sergio Venanzio Setola; Francesco Izzo; Luigi Scarpato; Vito Vanella; Lucia Festino; Ester Simeone; Paolo Antonio Ascierto; Antonella Petrillo
Journal:  Radiol Med       Date:  2022-07-14       Impact factor: 6.313

6.  Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.

Authors:  Vincenza Granata; Elisabetta de Lutio di Castelguidone; Roberta Fusco; Orlando Catalano; Mauro Piccirillo; Raffaele Palaia; Francesco Izzo; Adolfo D'Errico Gallipoli; Antonella Petrillo
Journal:  Radiol Med       Date:  2015-09-07       Impact factor: 3.469

Review 7.  The Role of Diffusion-Weighted Imaging (DWI) in Locoregional Therapy Outcome Prediction and Response Assessment for Hepatocellular Carcinoma (HCC): The New Era of Functional Imaging Biomarkers.

Authors:  Johannes M Ludwig; Juan C Camacho; Nima Kokabi; Minzhi Xing; Hyun S Kim
Journal:  Diagnostics (Basel)       Date:  2015-11-30

8.  Combination of transcatheter arterial chemoembolization and CT-guided percutaneous segment ablation for hepatocellular carcinoma therapy: A retrospective study.

Authors:  Wei Li; Yang Wang; Wenfeng Gao; Jiasheng Zheng
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

Review 9.  A Systematic Review about Imaging and Histopathological Findings for Detecting and Evaluating Electroporation Based Treatments Response.

Authors:  Vincenza Granata; Roberta Fusco; Simona Salati; Antonella Petrillo; Elio Di Bernardo; Roberta Grassi; Raffaele Palaia; Ginevra Danti; Michelearcangelo La Porta; Matteo Cadossi; Gorana Gašljević; Gregor Sersa; Francesco Izzo
Journal:  Int J Environ Res Public Health       Date:  2021-05-24       Impact factor: 3.390

Review 10.  Diagnostic evaluation and ablation treatments assessment in hepatocellular carcinoma.

Authors:  Vincenza Granata; Roberta Grassi; Roberta Fusco; Andrea Belli; Carmen Cutolo; Silvia Pradella; Giulia Grazzini; Michelearcangelo La Porta; Maria Chiara Brunese; Federica De Muzio; Alessandro Ottaiano; Antonio Avallone; Francesco Izzo; Antonella Petrillo
Journal:  Infect Agent Cancer       Date:  2021-07-19       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.